Expect near-term selling pressure from the dilutive ADS offering at a ~3% discount to the prior close. Monitor the September 11 EGM for shareholder approval outcomes on the Australian tranche and warrants. The warrant overhang at US$3.79 per ADS may cap upside through 2029.
Price Chart
Executive Summary
Radiopharm Theranostics announced a dilutive capital raise comprising a US$4.1 million registered direct offering of ADSs at US$3.16 per ADS, a concurrent private placement of warrants, and up to an additional A$12.7 million (US$8.9 million) in Australian placement and share purchase plan. The combined gross proceeds of up to ~US$13 million represent a significant dilution for a company with a $55M market cap, though the funds are earmarked for a registrational study and pipeline advancement. The dilutive structure and reliance on shareholder approval for a portion of the raise are bearish signals for existing shareholders.
Key Facts
- US$4.1 million registered direct offering of 1,281,646 ADSs at US$3.16 per ADS
- Concurrent private placement of warrants to purchase up to 1,281,646 ADSs at US$3.79 per ADS, expiring July 31, 2029
- Additional A$6.7 million (US$4.7 million) Australian Placement from institutional investors
- Share Purchase Plan for up to A$6 million (US$4.2 million) for Australian/New Zealand shareholders
- Combined potential gross proceeds of approximately US$13 million
- Proceeds intended for RAD101 registrational study, therapeutic programs, and working capital
- H.C. Wainwright & Co. acting as exclusive U.S. placement agent
- Shareholder approval required for Australian Placement portion and Share Purchase Plan, with EGM expected on or about September 11, 2026
Financial Impact
Up to ~US$13 million in gross proceeds from combined offerings, representing ~24% of market cap in new capital at a dilutive price
Risk Factors
- Dilution from up to 384.5M ordinary shares via ADS offering plus additional shares from Australian placement and SPP
- Warrant overhang of up to 1,281,646 ADSs exercisable at US$3.79
- Shareholder approval risk for Australian tranche and SPP
- Clinical-stage biotech with no approved products and ongoing cash burn
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-081114 |
| Document: ea029915801ex99-1.htm | 0001213900-26-081114 |
| Document: 0001213900-26-081114-index-headers.html | 0001213900-26-081114 |
| Document: 0001213900-26-081114-index.html | 0001213900-26-081114 |
| Document: 0001213900-26-081114.txt | 0001213900-26-081114 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+5 | — | — |
Oct 20, 2026 6d ago | 6-K | $0.9900 | awaiting T+5 | — | $1.01 (+2.02%) |
Oct 14, 2026 11d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $1.01 (−6.48%) |
Oct 5, 2026 21d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $1.01 (−20.47%) |
Oct 1, 2026 25d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $1.01 (−31.76%) |
Sep 30, 2026 26d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $1.01 (−37.65%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $1.01 (+35.75%) |
Sep 22, 2026 4w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $1.01 (−38.79%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $1.01 (−49.75%) |
Sep 11, 2026 6w ago | 6-K | $1.98 $1.65 | ▼ −16.67% | ▼ −16.45% | $1.01 (−48.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers